News

25 Feb
2020

Scipio bioscience announces its Series A fund raising

A total of €6.0m has been obtained from an international syndicate led by M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck. The initial shareholders Seventure Partners’ Quadrivum I (Paris, France) and High-Tech Gründerfonds (Bonn, Germany) participated in the capital increase, alongside additional investors Financière Arbevel (Paris, France) and Investiere Venture Capital (Zürich, Switzerland). Read the full press release here.

Scipio Distirbutors

Newsletter

Sign up to receive hands-on tips, technical reviews and experts opinions about single-cell technology. Every two months in your mailbox.